Solid Biosciences Inc（SLDB）資訊與事件SLDBSolid Biosciences Inc

Solid Biosciences CEO Highlights Progress on SGT-003

Bo Cumbo, President and CEO of Solid Biosciences, stated: "Our progress in the first half of 2026 positions us for continued momentum as we approach multiple key clinical and regulatory milestones across our Duchenne, Friedreich's ataxia and broader precision genetic medicine platform over the next several quarters. In Duchenne, we continue to have confidence in SGT-003's safety profile, which is achieved using a low-burden, steroid-only immunomodulation regimen. We are also highly encouraged by the strength of the biomarker data we have generated to date, which demonstrates promising biologic activity. As we prepare to analyze 12-month clinical data from initial participants in the INSPIRE DUCHENNE trial, we gain an important opportunity to evaluate the relationship between these biologic signals and clinical outcomes. We look forward to continued engagement with the FDA as we work with urgency to evaluate a potential accelerated approval pathway for SGT-003."

Solid Biosciences Doses First Participant in IMPACT DUCHENNE Trial

Solid Biosciences announced that the first participant has been dosed in IMPACT DUCHENNE, the company's multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003 for the treatment of Duchenne muscular dystrophy.

Solid Biosciences SGT-003 Receives EU Orphan Drug Designation

Solid Biosciences announced that the European Commission, acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy.